nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine, and space exploration Commitment to innovation, operational First-Quarter 2025 Earnings Call Presentation on ensuring the highest ESG standards Reported May 5, 2025 Our Purpose: We employ nuclear technology to solve some of the world's most important problems Our Mission: We provide safe and effective excellence, a strong safety record, and a focus Forward-Looking Statements Disclaimer Our Purpose: We employ nu ...

Financial Data and Key Metrics Changes - First quarter revenue was $682 million, up 13% year over year, with growth in both segments [21] - Adjusted EBITDA was $130 million, also up 13% year over year, driven by robust growth in government operations [21] - Adjusted earnings per share increased to $0.91, a 20% rise compared to $0.76 last year [22] Business Line Data and Key Metrics Changes - Government operations saw a revenue increase of 14%, driven by naval propulsion and special materials [24] - Commercial operations revenue was $128 million, up 10% year over year, led by growth in medical and commercial power [25] - Adjusted EBITDA margin for government operations was 21.1%, while commercial operations saw a margin of 10.9%, down 100 basis points due to unfavorable mix and cost absorption [26] Market Data and Key Metrics Changes - The commercial operations backlog reached a record $1.3 billion, up 39% from the previous quarter and 78% year over year [15] - The Canadian Nuclear Safety Commission authorized the construction of the first BWRX 300 unit, marking a significant milestone for North America's first SMR project [16] Company Strategy and Development Direction - The company is focused on expanding its nuclear services portfolio and enhancing its manufacturing capacity in North America [7][17] - BWXT is positioned to benefit from long-term investments in nuclear technologies driven by decarbonization and increasing electricity demand [5][6] - The company is actively pursuing opportunities in government contracts, particularly in energy security and environmental restoration projects [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to weather macroeconomic disruptions due to long-cycle contracts and a strong balance sheet [8] - The administration's focus on naval nuclear fleet and nuclear modernization is expected to support a revenue CAGR of 3% to 5% in the government operations segment [11] - The market for nuclear medicine is anticipated to grow significantly, driven by increasing volumes of SPECT and PET scanning procedures [20] Other Important Information - Free cash flow for the quarter was $17 million, with capital expenditures at $33 million, or 4.9% of sales [21][23] - The company expects full-year free cash flow to be between $265 million and $285 million [23] Q&A Session Summary Question: Were the negative EACs all at government operations? - The negative EACs were about half from commercial operations and half from government operations, with specific impacts noted in the fuel business [32][33] Question: Do you see BWXT as in line to get any of the funding from the recent appropriations? - There is optimism regarding potential funding from the reconciliation bill, particularly for domestic defense enrichment and DoD nuclear reactors [36][42] Question: Can you provide an update on the Actinium-225 effort? - The company remains the largest commercial producer of Actinium-225 and is exploring multiple production modalities [98] Question: What is the status of the enrichment contract and pilot program? - The pilot program is in the conceptual stage, focusing on designing a pilot plant for centrifuge-type enrichment technology [62][63] Question: How is the company managing the zirconium cost impact? - The company has strong relationships with customers that allow for a path through mechanism to mitigate unforeseen risks related to raw material costs [89]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ ...

"BWXT's foundation is providing our customers with mission critical nuclear products and solutions, and I am proud of the diversified and resilient portfolio we have built over our nearly ten years as a standalone company," continued Geveden. "Our vertically integrated nuclear capabilities, unique infrastructure, and highly-skilled workforce enable our customers to put their trust in BWXT to support their most important programs through all economic cycles in the global security, clean energy, and nuclear m ...

BWX Technologies, Inc. (BWXT) is scheduled to report first-quarter 2025 results on May 5, 2025, after market close.BWXT’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 10.33%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Revenues in BWXT’s Government Operations Likely to RiseHigher manufacturing volume of nuclear components for U.S. Government programs, along with growth in design and engineering work executed by the ...

Investors might want to bet on BWX Technologies (BWXT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

BWX Technologies (BWXT) shares soared 11.7% in the last trading session to close at $104.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.9% loss over the past four weeks.The latest uptick in BWX Technologies’ share price can be attributed to the recent award worth $2.6 billion, which the company received from the U.S. Department of Energy, to manage and operate the Strategic Petroleum Reserve.This supplier of nuclear fuel a ...

Core Insights - APTIM and BWX Technologies have been awarded a $1.4 billion contract by the US Department of Energy to manage and operate the Strategic Petroleum Reserve for a five-year term, with a potential five-year extension [1][2] - The Strategic Petroleum Reserve is the world's largest supply of emergency crude oil, holding 714 million barrels, aimed at minimizing disruptions in US petroleum supplies during international oil shortages [3] Company Overview - APTIM focuses on enhancing environmental quality, community resilience, and employee opportunities, providing integrated solutions in environmental, sustainability, and infrastructure sectors [4] - BWX Technologies is a Fortune 1000 company specializing in nuclear solutions for global security, clean energy, and environmental restoration, with approximately 7,800 employees and 14 major operating sites [5]

BWX Technologies, Inc. ( BWXT ) is a major player in the energy field, where federal projects drive about 80% of its income. That income is getting a boost from smart acquisitions—like Aerojet Ordnance Tennessee and Kinectrics—that give the company aI am an individual investor with over five years of experience in personal investing, holding a PhD in Economics from UCEMA. I serve as Chief Economist at CEEAXXI and Director of Financial Development at Luxury Entertainment CrowdTech. My investment approach foc ...

Although early, the BWRX-300 looks like a potential international franchise SMR with meaningful benefits to BWX Technologies. BWXT Medical has consequential growth potential from regulatory approval of its Tc-99 platform and Ac-225, the latter depending on clinical trial results. Early indications are that alpha radiation can be a real game changer in cancer treatment as its damage proves too much for even cancers' many repair mechanisms to overcome. Seaport Global analyst Jeff Campbell on Tuesday initiated ...